Breast cancer is the most common form of cancer in Canadian women, accounting for one in four cancer diagnoses. It is also the second leading cause of cancer deaths, after lung cancer. Determining a breast cancer patient’s response to chemotherapy at an early stage of treatment could allow doctors to more quickly determine whether patients would do better with another therapy. Laurentian University’s Dr. Amadeo Parissenti, along with Health Science North Dr. Baoqing Guo, have come up with a test that can do exactly that, measuring the effectiveness of chemotherapy as early as a patient’s first treatment. It is called a RNA Disruption Assay.
The technology has been licensed to Rna Diagnostics Inc. The knowledge generated by this patented assay will improve patient treatment, experiences, and outcomes for breast cancer patients around the world.
